Current Issues in the Psychopharmacology of Schizophrenia

by Breier, Alan

• ISBN13: 9780781724227
• ISBN10: 0781724228
• Format: Hardcover
• Copyright: 2001-05-01
• Publisher: Lippincott Williams & Wilkins

Summary

This text presents a broad-based review of the contemporary field of drugs for schizophrenia and is intended for graduate and postgraduate students and mental health professionals. It consists of 34 chapters by well-known experts in the field addressing basic mechanisms in the pathophysiology of schizophrenia, neuropharmacology, experimental strategies, atypical antipsychotics, and other clinical issues.

Table of Contents

Acknowledgments	xv
Contributing Authors	ix
Introduction The New Pharmacotherapy of Schizophrenia	xvii
Steven M. Paul
Section I. Basic Mechanisms in the Pathophysiology of Schizophrenia
Neurotransmitters-Dopamine and Beyond	3	(9)
Arvid Carlsson
Neuroanatomy: A Regional Understanding	12	(15)
Susan K. Schultz
Peg C. Nopoulous
Nancy C. Andreasen
The Neurodevelopmental Hypothesis of Schizophrenia: A Review of the Evidence	27	(30)
Robert K. McClure
Daniel R. Weinberger
Neuropathology of Schizophrenia	57	(16)
Vahram Haroutunian
Kenneth L. Davis
Section II. Neurobehavioral Pharmacology in Schizophrenia
The Dopamine Receptor Basis of Psychosis	73	(12)
Philip Seeman
Shitij Kapur
Application of Pharmacogenetics to Schizophrenia: Emerging Insights from Studies of Clozapine Response and Tardive Dyskinesia	85	(26)
Vincenzo S. Basile
Mario Masellis
Vural Ozdemir
Herbert Y. Meltzer
Fabio M. Macciardi
James L. Kennedy
Animal Behavioral Models of Schizophrenia	111	(20)
Clinton D. Kilts
Neuroimaging and the Pharmacological Treatment of Schizophrenia	131	(17)
Mark E. Schmidt
Neurophysiology and Psychophysiology	148	(44)
Kimberle A. Kelly
Keith H. Nuechterlein
Neurocognition	192	(17)
Richard S.E. Keefe
Section III. Second Generation Antipsychotics in the Treatment of Schizophrenia
Clozapine	209	(15)
John M. Kane
Handan Gunduz
Anil K. Malhotra
Olanzapine	224	(19)
Seiya Miyamoto
Gary E. Duncan
Jeffrey A. Lieberman
Resperidone	243	(9)
Stephen R. Marder
Quetiapine	252	(10)
Joyce G. Small
Sertindole	262	(17)
David G. Daniel
Laura F. Copeland
Section IV. Novel Therapeutic Strategies in Schizophrenia
Partial Dopamine Agonists in the Treatment of Psychotic Illness	279	(10)
Carol A. Tamminga
Robert A. Lahti
Adrienne C. Lahti
Arvid Carlsson
Serotonin as a Target for Antipsychotic Drug Action	289	(15)
Herbert Y. Meltzer
Targeting the Glutamate System	304	(29)
Walid M. Abi-Saab
D. Cyril D'Souza
Steven H. Madonick
John H. Krystal
Possible Role of Muscarinic Receptor Agonists as Therapeutic Agents for Psychosis	333	(16)
Frank P. Bymaster
Neuropeptides	349	(26)
Elisabeth B. Binder
Becky Kinkead
Charles B. Nemeroff
Section V. Clinical Issues in the Treatment of Schizophrenia
Childhood-Onset Schizophrenia	375	(14)
David W. Dunn
Christopher J. McDougle
Predictors of Schizophrenia and Preventive Intervention	389	(18)
Barbara A. Cornblatt
Positive Symptoms, Negative Symptoms, and Beyond	407	(10)
Beng-Choon Ho
Nancy C. Andreasen
Geriatric Schizophrenia	417	(13)
Jeremy A. Sable
Jonathan Lacro
John S. Kennedy
Dilip V. Jeste
Long-term Therapeutic Management in Schizophrenia	430	(17)
John M. Kane
Management of Suboptimal Treatment Response	447	(12)
George M. Simpson
Edmond H. Pi
Ethnic Issues in Schizophrenia	459	(11)
Keh-Ming Lin
Margaret T. Lin
Pharmacoeconomics of the New Atypical Antipsychotics	470	(19)
Dennis A. Revicki
Section VI. Special Issues in the Treatment of Schizophrenia
Gender Issues in the Psychopharmacology of Schizophrenia	489	(8)
Mary V. Seeman
Role of the Novel Antipsychotics in the Treatment of Comorbid Mood Disorders in Schizophrenia	497	(16)
Gary D. Tollefson
Dementia in Schizophrenia	513	(21)
Alexander Prikhojan
Kenneth L. Davis
Movement Disorders in Schizophrenia	534	(10)
Barry Jones
Current Issues in the Psychopharmacology of Schizophrenia in Japan	544	(12)
Anri Aoba
Leyna T. Mulholland
Psychopharmacology and Social Reintegration	556	(19)
Kimberly H. Littrell
Index	575